NO314438B1 - Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav - Google Patents
Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav Download PDFInfo
- Publication number
- NO314438B1 NO314438B1 NO19961979A NO961979A NO314438B1 NO 314438 B1 NO314438 B1 NO 314438B1 NO 19961979 A NO19961979 A NO 19961979A NO 961979 A NO961979 A NO 961979A NO 314438 B1 NO314438 B1 NO 314438B1
- Authority
- NO
- Norway
- Prior art keywords
- cyclodextrin
- estramustine
- pharmaceutical composition
- drug
- composition according
- Prior art date
Links
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title description 7
- 238000009472 formulation Methods 0.000 title description 6
- 229960001842 estramustine Drugs 0.000 title description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 75
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims description 33
- 229910019142 PO4 Inorganic materials 0.000 claims description 28
- 239000010452 phosphate Substances 0.000 claims description 28
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 5
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 11
- 239000001110 calcium chloride Substances 0.000 description 11
- 229910001628 calcium chloride Inorganic materials 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 238000001226 reprecipitation Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000012738 dissolution medium Substances 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- -1 chlorine ions Chemical class 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9419153A GB9419153D0 (en) | 1994-09-22 | 1994-09-22 | Estramustine formulations with improved pharmaceutical properties |
| PCT/EP1995/003438 WO1996009072A1 (en) | 1994-09-22 | 1995-09-01 | Estramustine formulations with improved pharmaceutical properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO961979D0 NO961979D0 (no) | 1996-05-14 |
| NO961979L NO961979L (no) | 1996-05-14 |
| NO314438B1 true NO314438B1 (no) | 2003-03-24 |
Family
ID=10761769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19961979A NO314438B1 (no) | 1994-09-22 | 1996-05-14 | Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5712260A (xx) |
| EP (1) | EP0730474B1 (xx) |
| JP (1) | JP3568957B2 (xx) |
| KR (1) | KR960705587A (xx) |
| CN (1) | CN1135719A (xx) |
| AT (1) | ATE219378T1 (xx) |
| AU (1) | AU698425B2 (xx) |
| CA (1) | CA2174968A1 (xx) |
| CZ (1) | CZ292125B6 (xx) |
| DE (1) | DE69527129T2 (xx) |
| DK (1) | DK0730474T3 (xx) |
| ES (1) | ES2179115T3 (xx) |
| FI (1) | FI962120A (xx) |
| GB (1) | GB9419153D0 (xx) |
| HU (1) | HUT75935A (xx) |
| IL (1) | IL115376A (xx) |
| MX (1) | MX9601852A (xx) |
| MY (1) | MY115689A (xx) |
| NO (1) | NO314438B1 (xx) |
| NZ (1) | NZ292895A (xx) |
| PL (1) | PL183132B1 (xx) |
| PT (1) | PT730474E (xx) |
| RU (1) | RU2179036C2 (xx) |
| TW (1) | TW496739B (xx) |
| UA (1) | UA48126C2 (xx) |
| WO (1) | WO1996009072A1 (xx) |
| ZA (1) | ZA957938B (xx) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9921954D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| GB9921958D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
| ITMI20031015A1 (it) * | 2003-05-20 | 2004-11-21 | Naxospharma S R L | Poli-(amminopirrolcarbossammidi) per uso nella profilassi e nel trattamento delle endoparassitosi animali e loro composizioni con ciclodestrine. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3299104A (en) * | 1963-04-09 | 1967-01-17 | Leo Ab | Certain steroid nu-bis-(haloethyl)-carbamates |
| JPS6327440A (ja) * | 1986-07-18 | 1988-02-05 | Sanraku Inc | グルコシル化分岐シクロデキストリン含有組成物 |
| SE8802402D0 (sv) * | 1988-06-28 | 1988-06-28 | Pharmacia Ab | Novel esters |
| GB8920135D0 (en) * | 1989-09-06 | 1989-10-18 | Erba Carlo Spa | Use of dehydrated cyclodextrins for improving drug dissolution |
| FR2667070A1 (fr) * | 1990-09-21 | 1992-03-27 | Besins Iscovesco Labo | Sterouides inclus dans des cyclodextrines procede pour leur preparation complexes et formes goleniques correspondants et leurs applications therapeutiques. |
-
1994
- 1994-09-22 GB GB9419153A patent/GB9419153D0/en active Pending
-
1995
- 1995-01-09 UA UA96062427A patent/UA48126C2/uk unknown
- 1995-07-31 TW TW084107923A patent/TW496739B/zh not_active IP Right Cessation
- 1995-09-01 ES ES95931963T patent/ES2179115T3/es not_active Expired - Lifetime
- 1995-09-01 WO PCT/EP1995/003438 patent/WO1996009072A1/en active IP Right Grant
- 1995-09-01 RU RU96113045/14A patent/RU2179036C2/ru not_active IP Right Cessation
- 1995-09-01 NZ NZ292895A patent/NZ292895A/en unknown
- 1995-09-01 AU AU35199/95A patent/AU698425B2/en not_active Ceased
- 1995-09-01 KR KR1019960702673A patent/KR960705587A/ko active IP Right Grant
- 1995-09-01 PL PL95314584A patent/PL183132B1/pl not_active IP Right Cessation
- 1995-09-01 MX MX9601852A patent/MX9601852A/es not_active IP Right Cessation
- 1995-09-01 CA CA002174968A patent/CA2174968A1/en not_active Abandoned
- 1995-09-01 JP JP51055096A patent/JP3568957B2/ja not_active Expired - Fee Related
- 1995-09-01 CN CN95190926A patent/CN1135719A/zh active Pending
- 1995-09-01 AT AT95931963T patent/ATE219378T1/de not_active IP Right Cessation
- 1995-09-01 DE DE69527129T patent/DE69527129T2/de not_active Expired - Fee Related
- 1995-09-01 US US08/635,956 patent/US5712260A/en not_active Expired - Fee Related
- 1995-09-01 DK DK95931963T patent/DK0730474T3/da active
- 1995-09-01 EP EP95931963A patent/EP0730474B1/en not_active Expired - Lifetime
- 1995-09-01 HU HU9601738A patent/HUT75935A/hu unknown
- 1995-09-01 PT PT95931963T patent/PT730474E/pt unknown
- 1995-09-01 CZ CZ19961456A patent/CZ292125B6/cs not_active IP Right Cessation
- 1995-09-20 ZA ZA957938A patent/ZA957938B/xx unknown
- 1995-09-21 MY MYPI95002797A patent/MY115689A/en unknown
- 1995-09-21 IL IL11537695A patent/IL115376A/xx not_active IP Right Cessation
-
1996
- 1996-05-14 NO NO19961979A patent/NO314438B1/no unknown
- 1996-05-20 FI FI962120A patent/FI962120A/fi not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jansook et al. | Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications | |
| EP0814844B1 (en) | Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same | |
| JP3579060B2 (ja) | アリール―複素環式化合物塩の包接錯体 | |
| KR100349754B1 (ko) | 제약조성물 | |
| AU2002246711B2 (en) | Complex of modafinil and cyclodextrin | |
| JPH08508711A (ja) | 塩基型薬剤と酸とシクロデキストリンを含有する高可溶性多成分包接錯体 | |
| AU2002246711A1 (en) | Complex of modafinil and cyclodextrin | |
| US6077871A (en) | Droloxifene pharmaceutical compositions | |
| JP2003063965A (ja) | 注射用シロスタゾール水性製剤 | |
| JP2003506458A (ja) | シクロデキストリン誘導体の包接複合体形成の増強 | |
| WO2008106721A1 (en) | Compositions and methods for delivery of anti-cancer agents | |
| NO314438B1 (no) | Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav | |
| JP2000507258A (ja) | ジクロフェナック／ガンマ―シクロデキストリン包接化合物 | |
| US7704975B2 (en) | Modafinil compound and cyclodextrin mixtures | |
| JPH07165616A (ja) | シクロデキストリンの複合組成物及び複合化法 | |
| CS85191A3 (en) | Inclusion complex of n-ethoxycarbonyl-3-morfolinosyd-nonimin and its salt with derivative of cyclodextrin | |
| Aiassa et al. | Cyclodextrin Multicomponent Complexes: Pharmaceutical Applications. Pharmaceutics 2021, 13, 1099 | |
| WO2006034849A1 (en) | Antitumoral pharmaceutical compositions comprising a spisulosine and a cyclodextrin | |
| MXPA98009888A (en) | Pharmaceutical compositions of droloxif |